These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Effect of iontophoretical application of NK1 receptor antagonists on pulpal blood flow in cats. Kim YK; Chu WS; Lee HJ; Ahn DK; Kim SK J Endod; 2005 Sep; 31(9):647-51. PubMed ID: 16123699 [TBL] [Abstract][Full Text] [Related]
43. Stimulatory effect of a specific substance P antagonist (RPR 100893) of the human NK1 receptor on the estradiol-induced LH and FSH surges in the ovariectomized cynomolgus monkey. Kerdelhué B; Gordon K; Williams R; Lenoir V; Fardin V; Chevalier P; Garret C; Duval P; Kolm P; Hodgen G; Jones H; Jones GS J Neurosci Res; 1997 Oct; 50(1):94-103. PubMed ID: 9379497 [TBL] [Abstract][Full Text] [Related]
44. The promise of substance P inhibitors in fibromyalgia. Russell IJ Rheum Dis Clin North Am; 2002 May; 28(2):329-42. PubMed ID: 12122921 [TBL] [Abstract][Full Text] [Related]
45. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P. Nizam E; Erin N Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097 [TBL] [Abstract][Full Text] [Related]
46. Lack of evidence for tachykinin NK1 receptor-mediated neutrophil accumulation in the rat cutaneous microvasculature by thermal injury. Pintér E; Brown B; Hoult JR; Brain SD Eur J Pharmacol; 1999 Mar; 369(1):91-8. PubMed ID: 10204686 [TBL] [Abstract][Full Text] [Related]
47. Behavioral sensitization induced by dorsal periaqueductal gray electrical stimulation is counteracted by NK1 receptor antagonism in the ventral hippocampus and central nucleus of the amygdala. Carvalho MC; Veloni AC; Genaro K; Brandão ML Neurobiol Learn Mem; 2018 Feb; 148():60-68. PubMed ID: 29519453 [TBL] [Abstract][Full Text] [Related]
48. The role of tachykinins in central nervous system inflammatory responses. Marriott I Front Biosci; 2004 Sep; 9():2153-65. PubMed ID: 15353277 [TBL] [Abstract][Full Text] [Related]
49. Substance P and the inflammatory and immune response. Mantyh PW Ann N Y Acad Sci; 1991; 632():263-71. PubMed ID: 1719871 [TBL] [Abstract][Full Text] [Related]
50. A flexible approach to the design of new potent substance P receptor ligands. Millet R; Goossens L; Bertrand-Caumont K; Goossens JF; Houssin R; Hénichart JP J Pharm Pharmacol; 2001 Jul; 53(7):929-34. PubMed ID: 11480541 [TBL] [Abstract][Full Text] [Related]
51. Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B. Culman J; Wiegand B; Spitznagel H; Klee S; Unger T Br J Pharmacol; 1995 Mar; 114(6):1310-6. PubMed ID: 7542533 [TBL] [Abstract][Full Text] [Related]
52. Substance P immunoreactivity increases following human traumatic brain injury. Zacest AC; Vink R; Manavis J; Sarvestani GT; Blumbergs PC Acta Neurochir Suppl; 2010; 106():211-6. PubMed ID: 19812951 [TBL] [Abstract][Full Text] [Related]
53. Effects of two novel tachykinin antagonists, FK224 and FK888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea-pigs in vivo. Hirayama Y; Lei YH; Barnes PJ; Rogers DF Br J Pharmacol; 1993 Mar; 108(3):844-51. PubMed ID: 7682142 [TBL] [Abstract][Full Text] [Related]
54. CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system. Lu P; Gonzales C; Chen Y; Adedoyin A; Hummel M; Kennedy JD; Whiteside GT Life Sci; 2009 Sep; 85(11-12):450-6. PubMed ID: 19632245 [TBL] [Abstract][Full Text] [Related]
55. Characterization of neurogenic inflammation in the airways of two highly inbred rat strains. Germonpré PR; Joos GF; Everaert E; Kips JC; Pauwels RA Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1796-804. PubMed ID: 8520739 [TBL] [Abstract][Full Text] [Related]
56. Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Bowden JJ; Garland AM; Baluk P; Lefevre P; Grady EF; Vigna SR; Bunnett NW; McDonald DM Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8964-8. PubMed ID: 7522326 [TBL] [Abstract][Full Text] [Related]
57. Substance P acts via the neurokinin receptor 1 to elicit bronchoconstriction, oxidative stress, and upregulated ICAM-1 expression after oil smoke exposure. Li PC; Chen WC; Chang LC; Lin SC Am J Physiol Lung Cell Mol Physiol; 2008 May; 294(5):L912-20. PubMed ID: 18326823 [TBL] [Abstract][Full Text] [Related]
58. A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12 hours after traumatic brain injury. Donkin JJ; Cernak I; Blumbergs PC; Vink R J Neurotrauma; 2011 Feb; 28(2):217-24. PubMed ID: 21175297 [TBL] [Abstract][Full Text] [Related]
59. Antagonists of sensory neuropeptides inhibit the secondary phase of increased circulation following thermally induced inflammation. Löfgren O; Qi Y; Lundeberg T; Gazelius B Microvasc Res; 1998 Nov; 56(3):228-32. PubMed ID: 9828161 [TBL] [Abstract][Full Text] [Related]
60. Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P. Burmeister AR; Johnson MB; Chauhan VS; Moerdyk-Schauwecker MJ; Young AD; Cooley ID; Martinez AN; Ramesh G; Philipp MT; Marriott I J Neuroinflammation; 2017 Dec; 14(1):245. PubMed ID: 29237453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]